Related Experiment Video
Updated: Jul 7, 2026
09:14
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
Haemorrhagic stroke during anti-platelet therapy
1Unità di Ematologia e Trombosi, Dipartimento di Medicina, Chirurgia e Odontoiatria, Ospedale San Paolo Università di Milano, Milano, Italy. marco.cattaneo@unimi.it
European Journal of Anaesthesiology. Supplement
|April 17, 2008
Summary
Anti-platelet drugs effectively reduce arterial events in atherosclerosis patients. While they slightly increase bleeding risk, this is generally outweighed by a significant reduction in ischemic strokes.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Medicine
Background:
- Platelet inhibition is crucial for preventing occlusive arterial events in atherosclerosis.
- Established anti-platelet agents include cyclo-oxygenase inhibitors, adenosine diphosphate receptor antagonists, and glycoprotein IIb/IIIa antagonists.
Purpose of the Study:
- To review the efficacy and risks of anti-platelet agents in cardiovascular and cerebrovascular event prevention.
- To compare the bleeding risk of anti-platelet agents with other antithrombotic drugs.
Main Methods:
- Literature review of anti-platelet drug classes and their clinical applications.
- Analysis of risk-benefit profiles, focusing on bleeding complications and stroke incidence.
Main Results:
- Aspirin and thienopyridines are used for long-term prevention, while all three classes are used in acute coronary syndromes and interventions.
- Anti-platelet agents carry a slightly increased risk of severe bleeding, including cerebral hemorrhage, but this is less than with anticoagulants or thrombolytics.
- The reduction in ischemic strokes typically outweighs the increase in hemorrhagic strokes.
Conclusions:
- Anti-platelet therapy offers a favorable risk-benefit ratio for patients with atherosclerosis.
- Combination therapy with aspirin and vitamin K antagonists may elevate cerebral hemorrhage risk.
Related Concept Videos
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...